Edition:
United States

Nestle SA (NESN.S)

NESN.S on Virt-X Level 1

83.50CHF
11:30am EST
Change (% chg)

CHF0.20 (+0.24%)
Prev Close
CHF83.30
Open
CHF83.10
Day's High
CHF84.08
Day's Low
CHF82.96
Volume
5,683,706
Avg. Vol
4,941,143
52-wk High
CHF86.40
52-wk Low
CHF72.92

Select another date:

Fri, Nov 16 2018

Nestle to shift Nespresso global HQ to Vevey to save money

ZURICH, Nov 16 Swiss food giant Nestle will relocate the headquarters of coffee business Nespresso in 2021 from Lausanne to the group's main campus in Vevey, 20 km (12 miles) away, to save money.

Consumers urge U.S. court to uphold Nestle non-GMO labeling lawsuit

A proposed class of consumers has asked a federal California court to reject Nestle USA Inc's motion to dismiss their lawsuit alleging the world's largest foodmaker misled shoppers about its "No GMO ingredients" label.

Nestle's Purina PetCare mulls French plant sale, job cuts

PARIS, Nov 13 Nestle's Purina PetCare division could cut around 200 jobs in France through voluntary departures and it is also exploring options for its Quimperle plant in Brittany, including a sale, said a Nestle France spokesman.

Nestle raises stake in food allergy drug developer Aimmune

The health science arm of Nestle SA will pay $98 million to raise its stake in Aimmune Therapeutics Inc, the drug developer said, as it prepares to submit a marketing application for its peanut allergy drug by the end of the year.

UPDATE 2-Nestle raises stake in food allergy drug developer Aimmune

Nov 12 The health science arm of Nestle SA will pay $98 million to raise its stake in Aimmune Therapeutics Inc, the drug developer said, as it prepares to submit a marketing application for its peanut allergy drug by the end of the year.

Nestle raises stake in food allergy drug developer Aimmune

Nov 12 The health science unit of Nestle SA would pay $98 million to increase its stake in Aimmune Therapeutics Inc, the drug developer for food allergies said on Monday.

Breakingviews - Private equity could scratch Nestlé skin-care itch

LONDON (Reuters Breakingviews) - Acne and other skin creams have had a spotty record at Nestlé, but a buyout group might do better. A unit at the world’s biggest food group that makes Botox rival Dysport may fetch at least 6 billion Swiss francs ($6 billion). Rival consumer groups may be put off by the business’s products and low margins, but they could appeal to a private equity firm. Facing pressure from activist Dan Loeb, Nestlé Chief Executive Mark Schneider announced a review of the divi

BRIEF-Nestle expects acceleration of growth in Q4, largely due to comps

* CEO SAYS STARBUCKS DEAL WILL SUPPORT NESTLE'S GLOBAL COFFEE BUSINESS GOING FORWARD

Price increases underpin sales growth at Nestle, Unilever

LONDON Nestle and Unilever , two of the world's biggest consumer goods makers, both reported a pick-up in quarterly sales on Thursday after getting higher prices for their products.

Breakingviews - Unilever and Nestlé’s growth tests pricing power

LONDON (Reuters Breakingviews) - Giant consumer goods companies are testing their pricing power. Charging more for products helped Unilever and Nestlé boost underlying revenue by 3.8 percent and 2.8 percent, respectively, in the third quarter. Both need the hikes to offset rising costs. The risk is that price-conscious customers go elsewhere.

Select another date: